Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives

GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.

GlaxoSmithKline Inc. abandoned its attempt to sell the alli brand and recommitted to promoting the beleaguered OTC weight loss aid, although it continues to drag down consumer health care product sales.

“We’re going to take the business back in hand and rebuild that brand in a much more focused way and see how that plays forward from here,” GSK Chief Financial Officer Simon Dingemans said July 25 during a conference

More from United States

More from North America

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By 

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.